Citations

Mayo Clinic

Showing 10 of 108523 citations.

Self‐regulated learning in simulation‐based training: a systematic review and meta‐analysis
Brydges, Ryan , Manzone, Julian, Hatala, Rose , Hamstra, Stanley J. , Zendejas, Benjamin , Cook, David A. , Shanks, David, Hamstra, Stanley J

Medical Education | March 20, 2015 | Volume: 49 | Issue: 4 | Pages: 368-378

10.1111/medu.12649 | PMID 25800297 Get It

Context Self‐regulated learning ( SRL ) requires an active learner who has developed a set of processes for managing the achievement of learning goals. Simulation‐based training is one context in which trainees can safely practise learning how to learn. Objectives The purpose of the present study was to evaluate, in the simulation‐based training context, the effectiveness of interventions designed to support trainees in SRL activities. We used the social‐cognitive model of SRL to guide a systematic review and meta‐analysis exploring the links between instructor supervision, supports or scaffolds for SRL , and educational outcomes. Methods We searched databases including MEDLINE and Scopus, and previous reviews, for material published until December 2011. Studies comparing simulation‐based SRL interventions with another intervention for teaching health professionals were included. Reviewers worked independently and in duplicate to extract information on learners, study quality and educational outcomes. We used random‐effects meta‐analysis to compare the effects of supervision (instructor present or absent) and SRL educational supports (e.g. goal‐setting study guides present or absent). Results From 11 064 articles, we included 32 studies enrolling 2482 trainees. Only eight of the 32 studies included educational supports for SRL . Compared with instructor‐supervised interventions, unsupervised interventions were associated with poorer immediate post‐test outcomes (pooled effect size: −0.34, p = 0.09; n = 19 studies) and negligible effects on delayed (i.e. > 1 week) retention tests (pooled effect size: 0.11, p = 0.63; n = 8 studies). Interventions including SRL supports were associated with small benefits compared with interventions without supports on both immediate post‐tests (pooled effect size: 0.23, p = 0.22; n = 5 studies) and delayed retention tests (pooled effect size: 0.44, p = 0.067; n = 3 studies). Conclusions Few studies in the simulation literature have designed SRL training to explicitly support trainees’ capacity to self‐regulate their learning. We recommend that educators and researchers shift from thinking about SRL as learning alone to thinking of SRL as comprising a shared responsibility between the trainee and the instructional designer (i.e. learning using designed supports that help prepare individuals for future learning).
New Horizons in Aortic Disease
Oderich, Gustavo S.

Journal of Endovascular Therapy | March 20, 2015 | Volume: 22 | Issue: 1 | Pages: 139-145

10.1177/1526602814566180 | PMID 25775695 Get It

Re: Distal Macro- and Microembolization During Subintimal Recanalization of Femoropopliteal Chronic Total Occlusions
Mendes, Bernardo C. , Oderich, Gustavo S. , Oderich, Gustavo S.

Journal of Endovascular Therapy | March 20, 2015 | Volume: 22 | Issue: 1 | Pages: 146-147

10.1177/1526602814565781 | PMID 25775696 Get It

Tumor-Infiltrating Dendritic Cells in Cancer Pathogenesis
Janco, Jo Marie Tran, Lamichhane, Purushottam , Karyampudi, Lavakumar, Knutson, Keith L. , Tran Janco, Jo Marie, Knutson, Keith L.

The Journal of Immunology | March 20, 2015 | Volume: 194 | Issue: 7 | Pages: 2985-2991

10.4049/jimmunol.1403134 | PMID 25795789 Get It

Abstract Dendritic cells (DCs) play a pivotal role in the tumor microenvironment, which is known to affect disease progression in many human malignancies. Infiltration by mature, active DCs into the tumors confers an increase in immune activation and recruitment of disease-fighting immune effector cells and pathways. DCs are the preferential target of infiltrating T cells. However, tumor cells have means of suppressing DC function or of altering the tumor microenvironment in such a way that immune-suppressive DCs are recruited. Advances in understanding these changes have led to promising developments in cancer-therapeutic strategies targeting tumor-infiltrating DCs to subdue their immunosuppressive functions and enhance their immune-stimulatory capacity.
Imaging of Cosmetic Plastic Procedures and Implants in the Body and Their Potential Complications
Yahyavi‐Firouz‐Abadi, Noushin , Menias, Christine O. , Siegel, Cary , Gayer, Gabriela, Katz, Douglas S. , Bhalla, Sanjeev

American Journal of Roentgenology | March 20, 2015 | Volume: 204 | Issue: 4 | Pages: 707-715

10.2214/ajr.14.13516 | PMID 25794060 Get It

iTagPlot: an accurate computation and interactive drawing tool for tag density plot
Ezenwoye, Onyeka, Cho, Hwan-Gue, Robertson, Keith D. , Choi, Jeong‐Hyeon , Kim, Sunghwan , Cho, Hwan-Gue, Robertson, Keith D

Bioinformatics | March 20, 2015 | Volume: 31 | Issue: 14 | Pages: 2384-2387

10.1093/bioinformatics/btv166 | PMID 25792550 Get It

Abstract Motivation: Tag density plots are very important to intuitively reveal biological phenomena from capture-based sequencing data by visualizing the normalized read depth in a region. Results: We have developed iTagPlot to compute tag density across functional features in parallel using multicores and a grid engine and to interactively explore it in a graphical user interface. It allows us to stratify features by defining groups based on biological function and measurement, summary statistics and unsupervised clustering. Availability and implementation: http://sourceforge.net/projects/itagplot/. Contact: jechoi@gru.edu and jeochoi@gmail.com Supplementary information: Supplementary data are available at Bioinformatics online.
Runx1 is associated with breast cancer progression in MMTV‐PyMT transgenic mice and its depletion in vitro inhibits migration and invasion
Browne, Gillian , Taipaleenmäki, Hanna , Bishop, Nicole , Madasu, Sharath C. , Shaw, Leslie M., Wijnen, André J. van , Stein, Janet L. , Lian, Jane B. , van Wijnen, Andre J, Shaw, Leslie M., Stein, Gary S. , van Wijnen, Andre J

Journal of Cellular Physiology | March 20, 2015 | Volume: 230 | Issue: 10 | Pages: 2522-2532

10.1002/jcp.24989 | PMID 25802202 Get It

Runx1 is a transcription factor essential for definitive hematopoiesis, and genetic abnormalities in Runx1 cause leukemia. Runx1 is functionally promiscuous and acts as either an oncogene or tumor suppressor gene in certain epithelial cancers. Recent evidence suggests that Runx1 is an important factor in breast cancer, however, its role remains ambiguous. Here, we addressed whether Runx1 has a specific pathological role during breast cancer progression and show that Runx1 has an oncogenic function. We observed elevated Runx1 expression in a subset of human breast cancers. Furthermore, throughout the course of disease progression in a classical mouse model of breast cancer (i.e., the MMTV‐PyMT transgenic model), Runx1 expression increases in the primary site (mammary gland) and is further upregulated in tumors and distal lung metastatic lesions. Ex vivo studies using tumor epithelial cells derived from these mice express significantly higher levels of Runx1 than normal mammary epithelial cells. The tumor cells exhibit increased rates of migration and invasion, indicative of an aggressive cancer phenotype. Inhibition of Runx1 expression using RNA interference significantly abrogates these cancer‐relevant phenotypic characteristics. Importantly, our data establish that Runx1 contributes to murine mammary tumor development and malignancy and potentially represents a key disease‐promoting and prognostic factor in human breast cancer progression and metastasis. J. Cell. Physiol. 230: 2522–2532, 2015. © 2015 Wiley Periodicals, Inc.
Prospective Randomized Trial of Moderately Strenuous Aerobic Exercise After an Implantable Cardioverter Defibrillator
Dougherty, Cynthia M. , Glenny, Robb W. , Burr, Robert L. , Flo, Gayle L. , Kudenchuk, Peter J.

Circulation | March 20, 2015 | Volume: 131 | Issue: 21 | Pages: 1835-1842

10.1161/circulationaha.114.014444 | PMID 25792557 Get It

Background— Despite its salutary effects on health, aerobic exercise is often avoided after receipt of an implantable cardioverter defibrillator (ICD) because of fears that exercise may provoke acute arrhythmias. We prospectively evaluated the effects of a home aerobic exercise training and maintenance program (EX) on aerobic performance, ICD shocks, and hospitalizations exclusively in ICD recipients. Methods and Results— A total of 160 patients (124 men and 36 women) were randomly assigned who had an ICD for primary (43%) or secondary (57%) prevention to EX or usual care (UC). The primary outcome was peak oxygen consumption, measured with cardiopulmonary exercise testing at baseline and 8 and 24 weeks. EX consisted of 8 weeks of home walking for 1 h/d, 5 d/wk at 60% to 80% of heart rate reserve, followed by 16 weeks of maintenance home walking for 150 min/wk. Adherence to EX was determined from exercise logs, ambulatory heart rate recordings of exercise, and weekly telephone contacts. Patients assigned to UC received no exercise directives and were monitored by monthly telephone contact. Adverse events were identified by ICD interrogations, patient reports, and medical charts. ICD recipients averaged 55±12 years and mean ejection fraction of 40.6±15.7; all were taking β-blocker medications. EX significantly increased peak oxygen consumption (EX, 26.7±7.0 mL/kg per minute; UC, 23.9±6.6 mL/kg per minute; P =0.002) at 8 weeks, which persisted during maintenance exercise at 24 weeks (EX, 26.9±7.7 mL/kg per minute; UC, 23.4±6.0 mL/kg per minute; P <0.001). ICD shocks were infrequent (EX=4 versus UC=8), with no differences in hospitalizations or deaths between groups. Conclusions— Prescribed home exercise is safe and significantly improves cardiovascular performance in ICD recipients without causing shocks or hospitalizations. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00522340.
An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis
Lynch, Patrick M, Burke, Carol A. , Phillips, Robin, Morris, Jeffrey S. , Slack, Rebecca, Wang, Xuemei , Liu, Jun , Patterson, Sherri, Rodrı́guez-Bigas, Miguel A. , Half, Elizabeth , Bülow, Steffen, Latchford, Andrew , Clark, Sue, Ross, William A., Malone, Bonnie, Hasson, Hennie, Hawk, Ernest T. , Lynch, Patrick M, Sinicrope, Frank A. , Richmond, Ellen S. , Burke, Carol A

Gut | March 20, 2015 | Volume: 65 | Issue: 2 | Pages: 286-295

10.1136/gutjnl-2014-307235 | PMID 25792707 Get It

Background and aim Although Non-steroidal anti-inflammatory drugs reduce colorectal adenoma burden in familial adenomatous polyposis (FAP), the utility of combining chemopreventive agents in FAP is not known. We conducted a randomised trial of celecoxib (CXB) versus CXB+diflouromethylornithine (DFMO) to determine the synergistic effect, if any. Methods The primary endpoint was % change in adenoma count in a defined field. Secondary endpoints were adenoma burden (weighted by adenoma diameter) and video review of entire colon/rectal segments. Adverse event (AEs) were monitored by National Cancer Institution toxicity criteria. Results 112 subjects were randomised: 60 men and 52 women at a mean age of 38 years. For the 89 patients who had landmark-matched polyp counts available at baseline and 6 months, the mean % change in adenoma count over the 6 months of trial was −13.0% for CXB+DFMO and −1.0% for CXB (p=0.69). Mean % change in adenoma burden was −40% (CXB+DFMO) vs −27% (CXB) (p=0.13). Video-based global polyp change was −0.80 for CXB+DFMO vs −0.33 for CXB (p=0.03). Fatigue was the only significant AE, worse on the CXB arm (p=0.02). Conclusions CXB combined with DFMO yielded moderate synergy according to a video-based global assessment. No significant difference in adenoma count, the primary endpoint, was seen between the two study arms. No evidence of DFMO-related ototoxicity was seen. There were no adverse cardiovascular outcomes in either trial arm and no significant increase in AEs in the CXB+DFMO arm of the trial. Differences in outcomes between primary and secondary endpoints may relate to sensitivity of the endpoint measures themselves. Trial registration number ClinicalTrials.gov number N01-CN95040.
The Top 12 Advances in Vascular Medicine
Olin, Jeffrey W. , Jang, James J., Rooke, Thom W. , Jaff, Michael R. , Beckman, Joshua A.

Journal of Endovascular Therapy | March 20, 2015 | Volume: 11 | Issue: 6_suppl | Pages: II-21-II-31

10.1177/15266028040110s606 | PMID 15760254 Get It

In the past decade, impressive strides have been made in the diagnosis and management of atherosclerotic, aneurysmal, and thromboembolic diseases, thanks in large part to the explosive growth in both vascular biology and clinical vascular medicine. We review what we consider to be the top 12 advances in this field: the discovery of nitric oxide, the metabolic syndrome, new thrombophilic disorders, therapeutic angiogenesis, endoluminal treatment of chronic venous disease, and a variety of drugs, including sildenafil, cilostazol, low-molecular-weight heparins, oral direct thrombin inhibitors, clopidogrel, statins, and angiotensin-converting enzyme inhibitors and angiotensin-receptor blocking agents.